Diagnosis & Disease Information

Bryant Furlow

October 10, 2014

Higher pancreastatin associated with worse survival times in surgically treated small bowel (SBNET) and pancreatic neuroendocrine tumors (PNETs).

Bryant Furlow

October 10, 2014

Lymph node ratio (LNR) may offer better survival prediction over the current measure for patients with carcinoid neuroendocrine tumors.

Bryant Furlow

October 10, 2014

Octreotide has demonstrated promising results vs. a subset of carcinoid tumors, despite a lower overall response rate.

Bryant Furlow

October 10, 2014

Tumor-specific mutations are common in high-grade neuroendocrine tumors.

Bryant Furlow

October 10, 2014

A 3-marker immunohistochemistry panel helps determine the primary site of malignancy in metastatic neuroendocrine tumors.

Next post in NANETS 2014 Symposium

$Everolimus Use in Sorafenib-Refractory Hepatocellular Carcinoma$

NANETS: Despite Dose Reductions, Everolimus Promising in Advanced Pancreatic Neuroendocrine Tumors